Fig 1.

A Scheme of the molecular structure of TGX221 and its analog BL05, as well as nanomicellar TGX221-BL05 formulation. Circled in red line indicates the modified position on TGX221 for conjugation with micelle polymers. Scale bar, 50 nm.

B Microscopic images of mice organs. Mice were treated with the solvent (PPG, 200 μl), TGX221-BL05 in polypropylene glycol (PPG) solution (naked TGX221) and nanomicellar TGX221 formulation (nano-TGX221). Drugs were injected via tail vein at a dose of 100 mg/kg bodyweight in 200 μl PPG solution. Animals were sacrificed at day 5 after drug delivery and the major organs as indicated on the left side of the panels were dissected for histological analysis after H&E staining. Magnification, × 200.

C. Tissue distribution of the delivered drug TGX221. Mice tissues harvested at autopsy described in panel B were homogenized for quantitative measurement of the TGX221 compound. Data were presented as Mean (n = 3) and error bars indicate the SEM. The asterisk indicates significant difference compared to the naked drug (P < 0.05, Student t-test).